Fig. 4

In vivo tri-modality imaging. a Fluorescence spectra of TPP, M, and MNPs. Inset picture is the fluorescent imaging related to the solution (1, TPP; 2, M, 3, MNPs). b Radio TLC chromatograms of ⁶⁴Cu@MNPs after 24 h incubation in mouse serum. c Plots of T₁⁻¹ versus Mn (or Gd) concentration for Mn@MNPs (or DTPA-Gd). d T₁-weighted MRI results (7T) obtained from aqueous solution of Mn@MNPs (or DTPA-Gd) at various Mn (or Gd) concentrations. e NIRFI of U87MG tumor-bearing nude mice following i.v. injection of MNPs. The white circle denotes the tumor site. f Ex vivo image of the main organs separated from U87MG tumor-bearing mice at 24 h post injection of MNPs. g PET image of U87MG tumor-bearing nude mice at 2, 4, 6, 12, 24, and 48 h post injection of ⁶⁴Cu@MNPs (150 μCi). The white circle denotes the tumor site. h In vivo T₁-weighted axial MRI images (7T) of the mice pre-injection and after injection of Mn@MNPs. The white circle denotes the tumor site. i Time-activity curves of the biodistribution of ⁶⁴Cu@MNPs in the blood, liver, spleen, and tumor (n = 3). j Quantitative biodistribution of ⁶⁴Cu@MNPs in the main organs 48 h post injection of ⁶⁴Cu@MNPs. H heart, Li liver, St stomach, Lu lung, K kidney, Br brain, Sp spleen, In intestine, Bl bladder, Pa pancreas, Bo bone, Mu muscle, T tumor. k Quantificational analysis of SNR ratio in tumor sites at 2, 4, 6, and 24 h post injection of Mn@MNPs or DTPA-Gd (n = 3). The data are expressed as means ± s.d